secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001193125-25-279091
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics Q3 cash $225.7M; UK/EU approval for FT819; first SSc patient treated
--------------------------------------------------------------------------------

- Cash, cash equivalents & investments $225.7M; projected runway through year-end 2027.
- Total revenue $1.7M from Ono collaboration; operating expenses $36.5M incl. $4.9M SBC.
- Received UK MHRA and EU EMA authorization to activate ex-US sites for FT819 in autoimmune disease.
- First systemic sclerosis patient treated in Phase 1 with fludarabine-free conditioning; no notable AEs.
- First patient (stage IV CRC) treated with FT836 MICA/B-targeted CAR T with no conditioning chemotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000119312525279091/0001193125-25-279091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000119312525279091/fate-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-279091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer